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Abstract 14 
Dispersive ionic liquid-liquid microextraction combined with liquid chromatography and UV 15 
detection was used for the determination of two antichagasic drugs in human plasma: nifurtimox and 16 
benznidazole. The effects of experimental parameters on extraction efficiency—the type and volume of ionic 17 
liquid and disperser solvent, pH, nature and concentration of salt, and the time for centrifugation and 18 
extraction—were investigated and optimized. Matrix effects were detected and thus the standard addition 19 
method was used for quantification. This microextraction procedure yielded significant improvements over 20 
those previously reported in the literature and has several advantages, including high inter-day reproducibility 21 
(relative standard deviation = 1.02% and 3.66% for nifurtimox and benznidazole, respectively), extremely 22 
low detection limits (15.7 ng mL-1 and 26.5 ng mL-1 for nifurtimox and benznidazole, respectively), and 23 
minimal amounts of sample and extraction solvent required. Recoveries were high (98.0% and 79.8% for 24 
nifurtimox and benznidazole, respectively). The proposed methodology offers the advantage of highly 25 
satisfactory performance in addition to being inexpensive, simple, and fast in the extraction and 26 
preconcentration of these antichagasic drugs from human-plasma samples, with these characteristics being 27 
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consistent with the practicability requirements in current clinical research or within the context of therapeutic 28 
monitoring.  29 
Highlights 30 
 An analytical procedure for the determination of two antichagasic drugs in plasma was proposed.  31 
 The procedure yielded a significant improvement over those reported in the literature. 32 
 The performance of the methodology was very satisfactory and requires very low amount of sample. 33 
 The technique is according to requirements in clinical research or therapeutic monitoring.  34 
35 
36 
37 
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Introduction 41 
 Chagas disease, also known as American trypanosomiasis—first described by Carlos Chagas in 1909 42 
[1]—is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi (T. cruzi). 43 
Chagas occurs mainly in Latin America, where transmission to humans is effected either through the feces of 44 
triatomine bugs or, in some cases, congenitally [2]. The disease affects approximately 16 to 18 million people, 45 
and more than 100 million people are exposed to the risk of infection [3]. In 2008 over 10,000 people were 46 
estimated to have died of Chagas disease. Because of the nonvector routes of infection—such as from mother 47 
to child, through blood transfusion, or via organ transplantation—the transmission of T. cruzi and the disease 48 
itself are no longer limited to Latin America, but rather have now become a worldwide problem [4,5]. Chagas 49 
disease has been rising in the ranking of international health priorities as a result of the growing extent of 50 
migration from endemic to nonendemic areas such as North America and Europe [6,7]. 51 
 Benznidazole (N-benzil-2-nitroimidazolylacetamide, BNZ) and nifurtimox (3-methyl-N-[(5-nitro-2-52 
furanyl)-methylene]-4-thiomorpholinamine-1,1-dioxide, NFX) are the only two drugs currently available for 53 
the treatment of Chagas disease, although BNZ is available in all the affected countries [8]. Both medicines 54 
are almost 100% effective in curing the disease if given soon enough after infection—i. e., up to the onset of 55 
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the acute phase. The efficacy of both drugs, however, diminishes the longer a person has been infected [1]. 56 
Nevertheless, the pharmacologic treatment of adults is associated with a greater than 30% incidence of 57 
adverse drug reactions [9], especially neuropathy and severe dermatologic and gastrointestinal symptoms, 58 
leading to treatment interruption in over 20% of the patients [10,11]. These pharmacologic characteristics 59 
imply the need for a close monitoring of the therapeutic agents. 60 
 BNZ is a chemotherapeutic drug currently used for the treatment of T. cruzi infections in both the 61 
chronic and acute phases. A few reports have been published on detection methods for BNZ. Raaflaub and 62 
Ziegler [12] investigated the bioavailability of the compound in plasma using polarography. Walton and 63 
Workman [13] determined BNZ and its metabolized amine derivative in blood plasma by high-performance 64 
liquid chromatography with ultraviolet detection (HPLC-UV) at a recovery of 90% and a reproducibility of 65 
3.2%. Barbeira and coworkers have studied direct–current and differential-pulse–polarographic methods for 66 
the analysis of BNZ in pharmaceutical formulations [14]. La-Scalea et al. investigated the voltametric 67 
behavior of BNZ with a glassy-carbon electrode and a DNA-biosensor [15]. The latter enabled the study of 68 
BNZ–DNA interactions through the use of immobilized DNA on the glassy–carbon–electrode surface. Only a 69 
few authors have developed an HPLC method to quantify BNZ in plasma and/or urine for further 70 
implementation in human pharmacokinetic and health-safety studies [12,16-18]. 71 
 A few methods have been published for the determination of' NFX in biologic fluids, including 72 
colorimetry with thin-layer chromatography [19] and HPLC [16,20]. By the former methodology, the results 73 
obtained of assays in serum, plasma, and urine after the oral administration of NFX to rats, dogs, and humans 74 
permitted a quantitative determination of the drug at a sensitivity of at least 0.5 μg mL-1. The latter approach 75 
resulted in the development of an easy sample-preparation procedure for pharmacokinetic studies in patients 76 
with chronic renal failure [19]. 77 
 The determination of clinically significant plasma BNZ or NFX concentrations has generated 78 
considerable interest. To our knowledge, two different contexts exist: the plasma concentrations of adults and 79 
children. A therapeutic range between 3 and 6 μg mL-1 in adult-plasma samples was originally proposed for 80 
both drugs on the basis of in-vitro data and the results from pharmacokinetic studies in adult humans, but 81 
lower values were observed for BNZ in the pediatric patients [21]. Similar values were obtained for NFX 82 
[20,22].  Recently, J. Altcheh and colleagues reported a high efficacy of BNZ in pediatric Chagas disease 83 
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despite the use of lower plasma concentrations than had been reported in adults. Thus, the plasma 84 
concentration of antichagasic drugs at the lower limit of clinical significance has yet to be determined 85 
definitively, especially in pediatric pharmacotherapeutics [21]. 86 
 Dispersive liquid-liquid microextraction (DLLME)—a novel method recently developed by Assadi 87 
and coworkers [23,24]—has been applied for the determination of several analytes in different matrices. This 88 
method is based on a ternary solvent system in which the extraction solvent (e. g., dichloromethane, octanol, 89 
toluene) and the miscible disperser solvent (e. g., methanol, acetonitrile, isopropanol) are rapidly injected into 90 
the aqueous sample by a syringe. The disperser solvent must be miscible with both the aqueous and the 91 
organic phases. At the beginning of the dispersion, exceedingly small droplets (with therefore a major 92 
surface-contact area) are formed that enable a maximal increase in mass transfer. Those droplets then collapse 93 
to form the ionic-liquid phase containing the analytes in an extremely small volume, thus achieving high 94 
enrichment factors. This last step can be speeded-up by centrifugation. 95 
 Room-temperature ionic liquids (RTILs)—a form of melting salts composed of organic cations and 96 
either organic or inorganic anions—have emerged as possible environmentally friendly solvents (aka green 97 
solvents) [25,26] and thus have achieved a wide application in the separation sciences [27-29], among other 98 
research areas, because of their unique properties—namely: low volatility, chemical and thermal stability, and 99 
good solubility in both organic and inorganic solvents. RTILs are progressively replacing the typical organic 100 
solvents in sample preparations. Ionic liquids (ILs) have been used as extractants in DLLME (i. e., for IL-101 
DLLME) in several studies such as the determination of nonsteroidal anti-inammatory drugs in urine by 102 
liquid chromatography and the ultraviolet detection [30] of insecticides [31] or polyaromatic hydrocarbons 103 
[32] in water samples. 104 
 In this investigation, we applied the IL-DLLME technique combined with HPLC-UV for the first 105 
time for the determination of BNZ and NFX levels in human plasma and both determined and optimized the 106 
effect of the critical experimental parameters on the extraction efficiency—namely, the nature and volume of 107 
the IL and disperser solvent, the pH, the type and concentration of salt, and the extraction and centrifugation 108 
times. 109 
 110 
2. Experimental 111 
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2.1. Chemicals and materials 112 
1-hexyl-3-methylimidazolium hexafluorphosphate, ([HMIM][PF6], 97.0% purity) was purchased 113 
from Fluka, Buchs, Germany. 1-butyl-3-methylimidazolium hexafluorphosphate ([BMIM][PF6]), 1-octyl-3-114 
methylimidazolium tetrafluoroborate([OMIM][BF4]), and 1-octyl-3-methylimidazolium hexafluorphosphate 115 
([OMIM][PF6]),  were synthesized in our laboratory through an adaptation of a procedure from the literature 116 
[29]. Reagents were of analytical grade or better: benznidazole (Roche, Buenos Aires, Industria Argentina), 117 
nifurtimox (Bayer, Leverkusen, Germany), 1-bromobutane, 98.0% (Riedel-de-Haën, Seelze, Germany), 118 
potassium hexafluorphosphate, 98.0% (Aldrich, WI, USA), 1-methylimidazole, 99.0% and phosphoric acid, 119 
85% w/w (Merck, Hohenbrunn, Germany), tetrafluoroboric acid, 48.0% w/v in water (Sigma-Aldrich, St. 120 
Louis, MO, USA), 1-bromoctane, 99.0% (Aldrich, WI, USA), hydrochloric acid and acetone, (Merck, Buenos 121 
Aires, Argentina), sodium hydroxide (Analar, Poole, England), potassium chloride, sodium chloride, 122 
trichloroacetic acid, sodium phosphate dibasic anhydrous and sodium bicarbonate (Anedra, Argentina), 123 
potassium phosphate (Matheson, Coleman & Bell, Norwood, OH, USA), magnesium sulfate 7-hydrate 124 
(Biopack, Argentina), potassium phthalate monobasic,  99.5% (Fluka, Buchs, Germany), sodium borate and 125 
methanol HPLC grade (Baker´s Analyzed, Phillipsburg, NJ, USA), acetonitrile and anhydrous ethanol (Carlo 126 
Erba, Divisione Chimica Industriale–Milano, Italy). Solutions were prepared with MilliQ® water. 127 
 The 100-μL and 25-μL microsyringes were respectively supplied by Hamilton, Reno, NV, USA and 128 
Agilent Technologies, Australia. The micropipettes were purchased from Eppendorf, Hamburg, Germany. 129 
 Conical graduated polypropylene light-blue screw-capped test tubes (17 x 120 mm, 15 mL) were used 130 
and the samples filtered through a Micro-Mate™ interchangeable syringe (Popper & Sons Inc., New Hyde 131 
Park, NY) containing a 0.22-μm cellulose-nitrate membrane. 132 
 133 
2.2. Instrumentation and chromatographic condition 134 
 An HP 1100 liquid chromatograph equipped with a binary pump, a thermostat-controlled column 135 
compartment, degasser, and variable-wavelength detector connected to a Data Apex CSW workstation (Data 136 
Apex, Czech Republic) was used. Chromatographic analysis was performed on a 250x4.6-mm ID (5-μm) 137 
Zorbax Eclipse XDB-C18 column (Agilent). Methanol-containing buffered phosphate (58:42; pH 2.70, 25 138 
mM) was used in the mobile phase. The organic phase was prefiltered through a 0.22-μm nylon membrane 139 
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(Osmonics-Magna) and the aqueous phase was prefiltered through a 0.45-μm cellulose-nitrate membrane 140 
(Micron Separations). The detector was set at 320 nm for BNZ and 395 nm for NFX, at which wavelengths 141 
the RTILs studied absorb no radiation. The injector (Rheodyne Model 7725i, Cotati, CA, USA) was fitted 142 
with a 5-μL loop. The flow rate was set at 1 mL min-1. 143 
 A LUGUIMAC LC-20 centrifuge operating at 4,200 rpm with 15-mL polypropylene tubes were used 144 
for the optimization experiments and an Eppendorf 5417 C/R centrifuge operating at 4,200 rpm for the 145 
quantification experiments—and the latter because of the low amounts of sample available. A Vortex Genie 2 146 
(Scientific Industries, Inc., USA) mixer was used for mixing the aqueous and the IL phases, and a combined 147 
glass Metrohm electrode in a commercial Accument AR 25 pH/mV/Ion/Meter (Fisher Scientific) pH meter 148 
gave the pH measurements. Water was puried with a Milli-Q system (Millipore Co.). 149 
 150 
2.3. Extraction procedure for the optimization experiments 151 
 The IL-DLLME was performed according to the following optimized procedure (see Section 3): 5.00 152 
mL of aqueous solution spiked with NFX (9.4 μg mL-1) or BNZ (5.6 μg mL-1) was placed in a 15-mL conical 153 
centrifuge tube. A mixture of 125 μL [OMIM][PF6] saturated with water and 0.30 mL methanol (the disperser 154 
solvent) was injected into the sample solution with a micropipette. After vortex-mixing, a cloudy solution was 155 
quickly formed. To increase the extraction efficiency, 0.1 g of KCl had been added. The analytes in the 156 
aqueous sample had become extracted into the fine ionic-liquid droplets at this step, while the methanol 157 
remained miscible in the aqueous solution. The mixture was then shaken for 6 min and centrifuged at 4,200 158 
rpm for 20.0 min. After this centrifuging, the droplets of ionic liquid had completely collected at the bottom 159 
of the centrifuge tube. The upper, aqueous phase was removed with a Pasteur pipette without disturbing the 160 
underlayer. The IL-phase volume was 120 ± 5 μL. Of the sedimented phase, 5 μL was withdrawn and injected 161 
into the HPLC column. All experiments were performed in triplicate. 162 
 163 
2.4. Extraction procedure for the human-plasma samples  164 
Human plasma spiked with different amounts of NFX and BNZ were acidified with 30% (w/v) 165 
trichloroacetic acid solution (0.10 mL in 1.00 mL of the sample) to remove the proteins. The mixture was then 166 
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shaken in a vortex for 6 min and centrifuged for 20 min. The supernatant was decanted and filtered through 167 
0.22-μm membranes into a 15-mL polypropylene tube. 168 
 The IL-DLLME was performed according to the following microscale-adapted procedure from 169 
Section 2.3: (1) To 540 μL of the supernatant, placed in a 2.0-mL polypropylene microcentrifuge tube, was 170 
added 32.4 μL of methanol containing 13.5 μL of [OMIM][PF6]. A cloudy solution resulted immediately as 171 
the analytes in the water sample became extracted into the fine droplets of the ionic liquid that were formed. 172 
(2) After adding 30 μL 1M NaOH to adjust the pH to the optimum  (pH=6.12) along with 0.011g of KCl, the  173 
salting-out effect was produced (3) The cloudy solution was vortex-mixed for 6 min, then centrifuged for 20.0 174 
min at 4,200 rpm to sediment the previously dispersed fine droplets of the ionic liquid into a unified volume 175 
at the bottom of the microcentrifuge tube. (4) Of this sedimented phase, 5 μL were withdrawn with a 25-μL 176 
microsyringe and then injected into the HPLC system for quantification. 177 
 178 
2.5. Preparation of stock and standard solutions in water and the sample matrix 179 
Stock solutions of NFX and BNZ were prepared by dissolving the compounds in methanol at 180 
concentrations of 940 and 560 μg mL-1, respectively. The solutions were sonicated for a few minutes in order 181 
to accelerate the dissolution. These stocks were stored in the refrigerator for up to one month and their 182 
preservation status checked daily by comparing the areas of relevant chromatographic peaks with the 183 
corresponding values obtained immediately after the solutions were prepared. 184 
 The standard solutions for the calibration curves were prepared both in water and in human plasma to 185 
evaluate possible matrix effects. Calibration curves in water were prepared by diluting the stock solutions 186 
with MilliQ® water and filtering through 0.22-μm cellulose-nitrate membranes. 187 
 Calibration curves in the sample matrix were prepared from human plasma free of NFX and BNZ. 188 
The samples were spiked with different volumes of the standard solutions. The solutions thus obtained were 189 
extracted by the procedure described in Section 2.5. Without dilution with any organic solvent, 5 μL of the 190 
resulting sedimented RTIL was injected into the HPLC column and analyzed under the aforementioned 191 
chromatographic conditions. The curves were obtained by plotting the peak areas vs. the concentrations of the 192 
analytes in the human plasma. 193 
 194 
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3. Results and discussion 195 
3. 1. Optimization of IL-DLLME 196 
 In order to choose the best experimental extraction conditions, a constant volume (5.00 mL) of the 197 
standard solution (cf. Section 2.6) was used in all the optimization experiments. As a consequence, in these 198 
experiments we did not use a specific concentration and, thus, the results shown in the figures correspond to 199 
the chromatographic areas reflecting the amount of analyte extracted into the IL phase relative to a constant 200 
initial amount. In the experimental procedure, a step-by-step optimization scheme was designed. Some 201 
significant parameters that would affect the extraction performance—namely, the nature and volume of the 202 
extraction and disperser solvents, the extraction and centrifugation times, the pH of the aqueous samples, and 203 
the type and salt concentration (for the salting-out effect) were studied and optimized. 204 
 205 
3. 1. 1. Selection of the ionic liquid 206 
 To select a given ionic liquid for a particular extraction is quite difficult since several water-207 
immiscible room-temperature ILs are commercially available [33-35]. The IL of choice should have a low 208 
miscibility in water, be denser than the matrix solution so that the microdroplets can be cleanly sedimented in 209 
order to be able to completely discard the aqueous phase thereafter, have good chromatographic behavior and 210 
a strong extraction affinity for the compound of interest, be inexpensive, and finally be directly injectable into 211 
the HPLC column. This last requirement, however, is not usually met since the IL must have a high viscosity, 212 
thus needing the addition of an organic solvent to make the organic phase sufficiently fluid before injection; 213 
and this step decreases the enrichment factor. For all these reasons, we selected the following imidazolium-214 
based ILs containing hexafluorophosphate or tetrafluoroborate anions with different alkyl chains: 215 
[BMIM][PF6], [HMIM][PF6], [OMIM][PF6] and [OMIM] ][BF4]. 216 
 Fig. 2 compares the extraction performance for the four ILs. The extractions were made in triplicate 217 
with the same initial volume of the standard solution (5.00 mL) and the same volume of the methanol-IL 218 
mixture (i. e., 0.50 mL/40 μL). All tubes were centrifuged for 20.0 min at 4,200 rpm. The IL [OMIM][PF6] 219 
produced the best extraction performance for both antichagasic drugs probably because stronger hydrophobic 220 
interactions were established between the longer alkyl chain of the IL and the analytes (Fig. 2). Thus, that IL 221 
was used for all of the subsequent experiments. 222 
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 223 
3. 1. 2. Selection of disperser solvent 224 
 The key feature of consideration for the selection of disperser solvent is the miscibility in both the IL 225 
phase (the extraction solvent) and the aqueous sample. Acetone, ethanol, acetonitrile, and methanol were 226 
considered in this experiment. A series of sample solutions were studied containing 0.50 mL of each disperser 227 
solvent plus 40 μL of [OMIM][PF6]. Since the chromatographic areas and, as a consequence, the extraction 228 
yields for the two drugs were found to be higher when methanol was used as the disperser solvent (Fig. 3), 229 
methanol was chosen for the subsequent experiments. 230 
 231 
3. 1. 3. Amount of ionic liquid 232 
 To evaluate the effect of the amount of IL, a constant volume of methanol (0.50 mL) containing 233 
different volumes of [OMIM][PF6] were used. By increasing the amount of IL, the extraction efficiency 234 
increased for the two antichagasic drugs, but after a maximum volume of 125 μL the chromatographic areas 235 
were seen to decrease (Fig, 4). Consequently, 125 μL of the IL was used as the optimum quantity for the 236 
sample extractions. 237 
 238 
3. 1. 4. Amount of disperser solvent 239 
 The volume of disperser solvent affects the solubility of the extraction solvent in the aqueous solution 240 
and, thus, the volume of sedimented phase. To obtain the optimal volume, experiments were performed with 241 
different methanol volumes containing the optimized amount of IL. The extraction was seen to increase up to 242 
0.30 mL of methanol as the result of a better solubilization of the IL which liquid therefore became atomized 243 
into progressively smaller microdroplets (Fig. 5). By increasing the volume of methanol, however, the 244 
extraction yield decreased because of a greater partitioning of the analytes into the aqueous phase. Thus, 0.30 245 
mL of methanol was indicated as the optimum volume. 246 
 247 
3. 1. 5. Effect of  pH  248 
 The effect of pH on the extraction efficiency was carried out within the pH range of 2.39 to 10.03. 249 
Different buffers were used depending on the desired pH (potassium phthalate monobasic at pH = 2.39 and 250 
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4.52, sodium phosphate at pH = 6.12, sodium borate at pH = 8.44 and sodium bicarbonate at pH = 10.03), but 251 
the ionic strength was kept constant (0.1 M) throughout. A mixture of 0.30 mL of methanol and 125 μL 252 
[OMIM][PF6],  was quickly added to the sample solution (Fig. 6). Although, to the best of our knowledge, the 253 
relevant pKa values were not available in the literature, the extraction proved to be maximum at pH = 6.12 so 254 
this pH was chosen for the experiments (Fig. 6). 255 
256 
3. 1. 6. Salt effects 257 
 The effect of salt addition was determined with four different salts: NaCl, KCl, MgSO4, and K3PO4. 258 
The extraction efficiency depended on the type and concentration of the salt added (Fig. 7). Previous reports 259 
had indicated that when certain salts were used in the aqueous phase for extraction with ILs, the electrostatic 260 
interaction between the salt ions and the IL ions enhanced the solubility of the IL in the aqueous phase and 261 
thus undermined the extraction efficiency [36-38]. In the present work, this effect was observed for NaCl, but 262 
for the other three salts an initial increase in the extraction was obtained as a result of the well known salting-263 
out effect. Furthermore, when KCl was used, the amount of recovered analyte was much higher than with the 264 
other salts (cf. the y-axes in Figs. 7A-D). Since for this salt a maximum was reached at 2.00% (w/v), this 265 
concentration of KCl was used. 266 
 267 
3. 1. 7. Extraction and centrifugation times 268 
 The centrifugation time was defined as the length of time the tube was inside the centrifuge.269 
Centrifugation helps to separate the IL phase from the aqueous phase particularly when highly viscous ILs 270 
tend to stick to the microtube wall, as occurred in this study. A series of extractions was performed with the 271 
centrifugation times varied from 3.0 to 60.0 min at 4,200 rpm, the maximum speed of the centrifuge. Since 272 
the chromatographic-peak area plateaued at 20 min (Fig. 8.A), this centrifugation time was considered 273 
optimal. 274 
 The extraction time was defined as the interval between the instant when the IL was added to the 275 
sample solution through the time in which both phases were in contact during shaking. This extraction time 276 
was varied between 1 and 20 min. The extraction efficiency increased up to 6.0 min and then reached a 277 
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plateau (Fig. 8.B). The two solvents obviously required a minimum time to reach equilibrium with the analyte 278 
and then separate. 279 
 280 
3.2. Analytical performance of the proposed methodology 281 
 The IL-DLLME–HPLC-UV method as developed in this systematic manner was then applied to the 282 
determination of BNZ and NFX in human plasma. The following figures of merit were evaluated: accuracy, 283 
reproducibility, limit of detection (LOD), limit of quantification (LOQ), the linearity range (LR), enrichment 284 
factor (EF), and extraction recovery (R%). 285 
 Calibration curves (Table 1) were made by linear regression of the peak areas vs. concentration in 286 
both water (thirteen levels) and human plasma (eight levels) for NFX and for BNZ. All determinations were 287 
made in triplicate. 288 
 In order to investigate if matrix effects were present for the quantitative determinations, we compared 289 
the slopes of the calibration curves obtained by the external-standard method for analytes dissolved in water 290 
with the slopes obtained by spiking the plasma samples. For the purpose of these comparisons, we chose the t-291 
test according to Equation 1 [39]: 292 
2
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The calculation of t' is not necessary if both regression lines are based on the same number of data points (n1 304 
= n2), in which circumstance t´= t1 = t2. The working curve in human plasma was compared with the standard 305 
one in water to detect matrix effects. For BNZ, the t´ value was 2.045, and the t was 3.07; whereas for NFX, 306 
the t´ value was 2.025, and the t was 58.95. Thus, since the t was higher than the t´ in both instances, we could 307 
conclude that the slopes were significantly different so that matrix effects were therefore present. As a 308 
consequence, for the quantification of BNZ and NFX in plasma samples, the standard addition method was 309 
used. 310 
 The LOD in human plasma was calculated by different procedures in order to make comparisons with 311 
other studies in the literature—for example, by using the signal to noise ratio (S/N) = 2.0, 3.0 and by using the 312 
IUPAC definition of LOD = 3.29 so [39] (based on the standard deflection of the concentration predicted for a 313 
blank sample, s0). 314 
 The lower LOQ in human plasma (at the beginning of the linear range) was evaluated by the S/N of 315 
10, and by the IUPAC definition of LOQ at 10 s0 [39]. The end point of the linear range (i. e., the upper limit 316 
of quantification) was determined by the lack-of-fit procedure [39]—i. e., by eliminating the highest value 317 
and applying the statistical test again with the remaining points. This process is repeated until the data can be 318 
adjusted to a straight line. 319 
 In order to validate the accuracy and precision of the determinations, each sample was spiked with the 320 
target drug at three different concentrations within the linear range of the calibration curve. The precision of 321 
the NFX and BNZ assay was determined by the repeatability (intra-day) and reproducibility (inter-day 322 
determinations) with samples containing 5.0, 7.5, and 10.0 μg mL-1 of NFX and BNZ. Reproducibility was 323 
expressed as the percent relative standard deviation (%RSD) with respect to measurements made in triplicate. 324 
The same drug concentrations were analyzed over three consecutive days to determine inter-day precision. 325 
 The enrichment factors (EFs) and recoveries (%Rs) were calculated by means of equations 3 and 4, 326 
respectively: 327 
aq
IL
C
CEF 
                    (3)
 328 
 329 
where CIL and Caq are the analyte concentrations in the IL phase and the initial aqueous solution, respectively, 330 
 331 
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 333 
where VIL and Vaq are the volumes of the IL phase and the sample solution, respectively, and  is the phase 334 
ratio. Plasma human samples were spiked with known volumes of NFX and BNZ solutions of known 335 
concentration (2.5, 5.0, 7.5, and 10.0 μg mL-1). The concentrations of the target analytes in the extracts were 336 
within the linear range of the calibration curves. The EF was calculated by Equation 3, after spiking a 337 
measured amount of analyte in a known volume of plasma and then determining the final concentration 338 
extracted into the RTIL phase. The analyte was left in contact with the plasma matrix for one hour before 339 
extraction. Recovery was determined by measuring the initial volume of spiked plasma and the final volume 340 
of RTIL phase and using the EF obtained in Equation 4. The recoveries obtained for NFX at different 341 
concentration levels were higher than those for BNZ (Table 3). As was discussed in our previous paper, the 342 
hydrophobic-interaction determines the extraction process with RTILs [29 and references therein]. Fig. 9 343 
shows the typical chromatograms of the two antichagasic drugs before and after IL-DLLME, in a spiked 344 
human plasma sample. The original sample was clearly spiked at a level in which the subsequent 345 
chromatographic-peak area could be measured (where the drug concentration for a sample obtained from a 346 
treated patient would not necessarily be so propitious). Table 4, however, further provides the antichagasic-347 
drug contents of human-plasma samples determined after the IL-DLLME was spiked to give a range of 348 
different concentrations of those agents. Nevertheless, even in this circumstance, the precision and 349 
reproducibility obtained for each level remained satisfactorily high. 350 
 The methodology for the determination of BNZ and NFX in human plasma proposed here was then 351 
compared with other methods extant in the literature, mostly consisting of direct matrix analyses by HPLC 352 
with UV detection or thin-layer chromatography. The LOD, LOQ, LR, reproducibility (%RSD), amount of 353 
sample necessary for the analysis, type and amount of solvent, and R% are presented in Table 5. Compared to 354 
these earlier examples, the IL-DLLME–HPLC-UV technique requires small amounts of extraction solvent 355 
(here a few microliters of an ionic liquid) and exhibits a wide range of linearity, very low limits of detection 356 
and quantification, and excellent reproducibility within and between samplings. The recoveries were 357 
moreover high for both NFX and BNZ. 358 
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 The methodology developed and described here is now being applied to the study of real samples—i. 359 
e., human plasma from infected patients—for future presentation of the findings.360 
361 
3.3. Conclusions 362 
 The IL-DLLME–HPLC-UV technique has been used here for the first time to analyze BNZ and NFX 363 
in human-plasma samples. The experimental conditions for the extraction of these analytes have been 364 
investigated and optimized. Although a step-by-step procedure to obtain the optimum extraction conditions 365 
was used,  the analytical methodology proved to have several advantages compared to other previously 366 
reported extraction techniques—namely, better reproducibility, lower detection limits, and the requirement for 367 
much lower amounts of extraction solvent. Moreover, the technique requires very small amounts of sample, 368 
which characteristic in the example of human plasma is a highly practical and desirable feature. Recovery was 369 
notably high for both compounds, and the performance of the proposed methodology was most satisfactory. 370 
Thus, the IL-DLLME-HPLC-UV technique promises to be a simple, fast, efficient, and facile method for the 371 
enrichment and quantitative determination of BNZ and NFX in human-plasma samples.372 
373 
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 444 
LEGENDS TO THE FIGURES445 
Fig. 1: Chemical structures of (a) nifurtimox; (b) benznidazole446 
447 
Fig. 2: Effect of the type of ionic-liquid on extraction efficiency (filled bars, BNZ; empty bars, NFX) 448 
 449 
Fig. 3: Effect of the nature of the disperser solvent on extraction efficiency (filled bars, BNZ; empty bars, 450 
NFX)451 
Fig. 4: Effect of the volume of the selected IL on extraction efficiency ( BNZ,  NFX). 452 
.453 
Fig. 5: Effect of the volume of the disperser solvent on extraction efficiency ( BNZ,  NFX).454 
455 
Fig. 6: Effect of pH on extraction efficiency ( BNZ,  NFX).456 
457 
Fig. 7: Effect of the type and concentration of salts on extraction efficiency ( BNZ,  NFX).458 
459 
Fig. 8: Effect of centrifugation and extraction times on extraction efficiency ( BNZ,  NFX). 460 
 461 
Fig. 9: Chromatograms for a spiked (5 μg mL-1) and a protein-free human-plasma sample before (continued 462 
line) and after (dotted line) IL-DLLME preconcentration.463 
Table 1: Calibration curves for NFX and BNZ464 
 465 
i. Calibration curves in water 466 
Analyte Linear regression R* SD* N* 
BNZ  y= (4.0 ± 2.1) + (2,050,088 ± 11821)x    0.9997 0.2 39
NFX y= (9.3 ± 4.8) + (4,468,983 ± 28293)x 0.9998 0.5 39
 467 
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ii. Calibration curves in plasma including DLLME 468 
Analyte Linear regression R* SD* N*
BNZ y= (0.16 ± 0.08) + (2,099,642 ± 10,983)x 0.9993 9.6 24
NFX  y= (1.5 ± 0.1) + (2,722,350 ± 8,790)x 0.9992 22.0 24
*R = regression coefficient; SD = standard deviation; N = number of points. 469 
470 
471 
Table 2: Limits of detection and quantification obtained for BNZ and NFX in human plasma  472 
(concentration units in μg mL-1) 473 
 474 
Compounds Linear range  LODa LODb LODc  LOQa LOQd
BNZ 0.1323-500.5 0.1009 0.0265 0.0397 0.3058 0.1323 
NFX 0.0784-908.7 0.0829 0.0157 0.0235 0.2514 0.0784 
afrom calibration curve (IUPAC definition) ; bS/N = 2, c S/N = 3,  dS/N = 10.  475 
 476 
477 
Table 3: Recoveries (%R) and enrichment factors (EF) for human plasma samples at different spiked 478 
 levels of NFX and BNZ. 479 
 480 
Spiking level  NFX  BNZ 
(g mL-1) EF R(%)a RSD(%)b  EF R(%)a RSD(%)b
2.5 
5 
7.5 
10 
38.7 
39.0 
39.2 
39.2 
96.8 
97.5 
98.1 
98.0 
0.5 
0.2 
0.1 
0.1 
 31.7 
31.24 
31.3 
31.9 
79.4 
78.1 
78.2 
79.8 
1.7 
0.1 
0.3 
0.6 
a recovery (n = 3), b %RSD for recovery. 481 
482 
483 
484 
485 
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486 
Table 4: Quantitative determinations of NFX and BNZ in spiked human plasma, accuracy and reproducibility  487 
(concentrations in g mL-1). 488 
 489 
 490 
Analyte Concentration  
added 
Concentration
founda
Accuracy 
(%) 
Reproducibility  
(%RSD) 
NFX     
Intra-day 
 
5 
7.5 
10 
4.9 ± 0.2 
 
7.3 ± 0.1 
 
9.8 ± 0.2 
-2.39 
 
-2.98 
 
-2.30 
1.79 
 
0.76 
 
0.97 
Inter-day 
 
5 
7.5 
10 
4.9 ± 0.2 
 
7.4 ± 0.2 
 
9.8 ± 0.2 
-2.27 
 
-1.43 
 
-2.30 
2.13 
 
1.53 
 
1.02 
BNZ     
Intra-day 
 
5 
7.5 
10 
5.0 ± 0.2 
 
7.6 ± 0.2 
 
10.0 ± 0.5 
0.025 
 
1.61 
 
-0.18 
1.56 
 
1.31 
 
2.52 
Inter-day 
 
5 
7.5 
10 
5.0 ± 0.2 
 
7.6 ± 0.3 
 
9.7 ± 0.7 
0.34 
 
1.61 
 
-3.38 
1.59 
 
1.89 
 
3.66 
a based on 9 levels, each one by triplicate. 491 
 492 
493 
494 
495 
496 
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Table 5: Comparison of the method of IL-DLLME-HPLC-UV developed with other procedures described in the 497 
literature for the determination of .BNZ and NFX in human plasma (NG: not given; WE: no extraction 498 
step used). 499 
 500 
Method Sample 
amount  (mL)
Extraction  
solvent (mL) 
Volume of extraction 
solvent (mL)
LR
(µg mL-1)
LOD 
(µg mL-1)
LOQ 
(µg mL-1)
R% RSD%d Ref.
BNZ          
HPLC-UV 0.075 WE WE 1.6–100 0.8 1.6 94.9 1.1 [8] 
HPLC-UV 0.2 ACN–DMSO 0.4 0.7–25 NG 0.7c 70–97 6.4 [40] 
HPLC-UV NG WE WE 0.5–1000 0.2–0.5b NG 90 3.2 [13] 
HPLC-UV 2.0 ethyl acetate 4.0 0.1–20 0.14e 0.3f 89 10 [41] 
IL-DLLME-
HPLC-UV   
0.54 [OMIM][PF6] 0.013 0.1–500 0.04a 0.1c 78.8 1.3 Our 
work
NFX          
HPLC-UV 1 CH2Cl2 3.5 0.08–2.3 0.08b NG 90.6 3.5 [20] 
TLC 10 ethyl acetate 40 0.5–10 0.1-0.2 NG 80 NG [19] 
IL-DLLME- 
HPLC-UV  
0.54 [OMIM][PF6] 0.013 0.08–908.7 0.02a 0.08c 97.6 0.76 Our 
work 
a S/N = 3;  b S/N = 2; c S/N = 10; d intra-day; e 3.3 s0; f 9 s0. 501 
 502 
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